Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Debt to Equity (2020 - 2022)

SAB Biotherapeutics (SABS) has disclosed Debt to Equity for 2 consecutive years, with $0.02 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Debt to Equity changed N/A year-over-year to $0.02, compared with a TTM value of $0.02 through Dec 2022, changed N/A, and an annual FY2022 reading of $0.02, changed N/A over the prior year.
  • Debt to Equity was $0.02 for Q4 2022 at SAB Biotherapeutics, up from $0.0 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.02 in Q4 2022 and bottomed at $0.0 in Q4 2020.